Kura Oncology, Inc. (KURA)
| Market Cap | 874.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -123.88M |
| Shares Out | 66.56M |
| EPS (ttm) | -1.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 818,582 |
| Open | 13.38 |
| Previous Close | 13.64 |
| Day's Range | 12.91 - 13.58 |
| 52-Week Range | 12.02 - 36.27 |
| Beta | 1.55 |
| Analysts | Buy |
| Price Target | 37.57 (+185.9%) |
| Earnings Date | Nov 4, 2021 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Kura Oncology stock is "Buy." The 12-month stock price forecast is 37.57, which is an increase of 185.92% from the latest price.
News
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and...
– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC –
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. ("Kura" or the "Company") (NASDAQ: KURA). Such investors are advised to contac...
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma –
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination wit...
– New findings presented at ASH support development strategy for KO-539 in KMT2A-rearranged and NPM1-mutant AML – – New findings presented at ASH support development strategy for KO-539 in KMT2A-rearran...
Why Kura Oncology Stock Is Sliding Today
A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.
See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial
The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Inc's (NASDAQ: KURA) cancer drugs following a patient's death in a clinical trial. Kura reported that the ...
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Management to host webcast and conference call today at 8:30 a.m. ET Management to host webcast and conference call today at 8:30 a.m. ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Participate in Credit Suisse Healthcare Conference
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Report Third Quarter 2021 Financial Results
SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Appoints Teresa Bair as Chief Legal Officer
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Reports Second Quarter 2021 Financial Results
– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 –
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Report Second Quarter 2021 Financial Results
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck ...
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors –
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539
– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose –
Kura Oncology to Participate in JMP Securities Life Sciences Conference
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Appoints Carol Schafer to Board of Directors
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of ...
Kura Oncology Reports First Quarter 2021 Financial Results
– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window –
Kura Oncology to Report First Quarter 2021 Financial Results
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –
Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck Cancer
The FDA has designated Breakthrough Therapy status to Kura Oncology Inc's (NASDAQ: KURA) tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for head and neck cancer. The status covers ...
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –